Edwards Lifesciences Raises Guidance on TAVR Momentum, Share Buyback
Event summary
- Edwards Lifesciences reported Q1 2026 sales of $1.65 billion, a 16.7% increase, with constant currency sales up 12.7%.
- TAVR sales reached $1.20 billion, growing 14.4% (11.0% constant currency), driven by strong performance both domestically and internationally.
- The company raised its FY 2026 constant currency sales growth guidance to 9-11% from 8-10% and adjusted EPS guidance.
- Edwards completed a $500 million accelerated share repurchase program.
The big picture
Edwards' strong performance and raised guidance reflect the increasing adoption of transcatheter valve therapies, driven by favorable clinical data and evolving treatment protocols. The company's focus on proactive disease management positions it to capitalize on a growing market, but regulatory and competitive pressures remain key factors to monitor. The accelerated share repurchase signals confidence in the company's long-term prospects and commitment to shareholder value.
What we're watching
- Regulatory Risk
- The CMS reconsideration of the TAVR NCD presents a significant opportunity for Edwards, but a negative decision could restrict access and impact sales growth. The outcome will be a key indicator of long-term market dynamics.
- Competitive Landscape
- While the exit of a European competitor boosted market share, new entrants or increased aggression from existing players could erode Edwards’ position, particularly as TAVR adoption broadens.
- Clinical Adoption
- The continued momentum behind proactive disease management and the PROGRESS trial results will be crucial for driving broader adoption of SAPIEN TAVR and expanding the addressable patient population.
Related topics